Wanbury's Tanuku API Facility Receives OAI Classification from US FDA
Wanbury Ltd 路 Press Release 路 16 Nov 2026, 7:43 pm
Wanbury's Tanuku API Facility Receives OAI Classification from US FDA The US FDA has classified the inspection of Wanbury Limited鈥檚 Active Pharmaceutical Ingredient (API) facility in Tanuku, Andhra Pradesh, conducted between 13th Jul'26 and 17th Jul'26, as Official Action Indicated (OAI). According to the company's assessment, this regulatory classification will not impact business continuity or existing customer product supplies from the site. Wanbury stated it will work closely with the regulator to maintain compliance and resolve identified issues.
Original exchange filing (PDF)
More announcements from Wanbury Ltd
- Clarifications on investor queries regarding recent announcement 路 16 Nov 2026
- Wanbury Limited received regulatory approval (CADIFA: Letter of suitability for API) from ANVISA (Brazil FDA) for its flagship product Metformin HC1 EP grade. 路 12 Nov 2026
- Press Release on Standalone and Consolidated Un-audited Financial Results for the second quarter & half year ended 30th September, 2026. 路 06 Nov 2026
- Financial Results as on 30th September, 2026 路 05 Nov 2026
- Outcome of the Board Meeting held on November 04, 2026 路 05 Nov 2026
- Wanbury Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 05 Nov 2026
- Wanbury Limited receives Australian TGA GMP Compliance Certificate for its Tanuku Plant, Strengthening Its Global Pharmaceutical Manufacturing Credentials. 路 30 Oct 2026
- Wanbury Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve the un-audited Financial Results (Standalone .... 路 04 Nov 2026
